Developer docs
API playgroundTry for free, no card

Search company profiles

BrainChild Bio

Full company profile

uuid0002s1o

Namestring
BrainChild Bio
Legal namestring
BrainChild Bio, Inc.
Company typeenum
Private
Founded yearint
2023
Descriptiontext

BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for tumors of the central nervous system, with a pediatric-first pipeline anchored by lead candidate BCB-276 in diffuse intrinsic pontine glioma (DIPG), an incurable childhood brainstem cancer. The company was launched in December 2023 as a spin-off from Seattle Children's, founded by Dr. Michael Jensen — inventor of over 200 cell and gene therapy patents and co-founder of Juno Therapeutics and Umoja Biopharma — and is led by CEO Steven Brugger (formerly CEO of Affinivax, acquired by GSK for $3.3 billion in 2022).

The company's core technology is a unified CAR-T platform built on three proprietary pillars: (1) recursive intracerebroventricular dosing that delivers CAR-T cells directly into the cerebrospinal fluid, bypassing the blood-brain barrier and eliminating the need for systemic lymphodepleting chemotherapy; (2) a multiplexed targeting portfolio against EGFR, HER2, B7-H3, and IL13Ralpha2 designed to prevent therapeutic failure from antigen escape; and (3) the PotencyPlus synthetic transgene library that augments CAR-T potency in the immunosuppressive tumor microenvironment. Beyond lead candidate BCB-276, the pipeline includes BCB-214 (PotencyPlus-enhanced, near-term Phase I) and additional clinical candidates BrainChild-01 through BrainChild-04 targeting HER2, B7-H3, and a quad-targeting construct.

BrainChild Bio is pre-revenue and generates no commercial product sales today. Its economics are entirely clinical-development-stage: it funds operations through grants (e.g., a $300,000 ScaleReady G-Rex Grant in January 2025) and is positioned to monetize via commercialization of CAR-T products following FDA approval. It received FDA Breakthrough Therapy Designation in April 2025 and RMAT designation in May 2025 for its B7-H3 program, enabling an expedited pivotal registrational pathway toward BLA. The company is headquartered in Seattle with a secondary presence at the Cambridge Innovation Center, operates with 11–50 employees, and its primary customers — once commercialized — will be pediatric patients with DIPG/DMG and, on pipeline extension, adult patients with glioblastoma and brain metastases.

Short descriptiontext

BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system tumors, spun out of Seattle Children's in 2023 to prioritize pediatric brain tumors, primarily DIPG, with planned expansion into adult glioblastoma and brain metastases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR T-cell therapy, CNS tumor immunotherapy, pediatric brain tumor treatment, intracerebroventricular dosing, DIPG cell therapy
Industry4 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAL
Neuro-oncology
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy / CAR-T Immunotherapy for CNS Tumors
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1CAR-T Therapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing CAR T-cell therapies for CNS tumors. Revenue will be generated through commercialization of proprietary cell therapy products following FDA approval. BCB-276 is the lead candidate for DIPG with pivotal trial pathway aligned with FDA.

brainchildbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system (CNS) tumors, with lead candidate BCB-276 (an autologous B7-H3-targeting CAR T-cell therapy) advancing toward a pivotal registrational trial for diffuse intrinsic pontine glioma (DIPG). The platform uses recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed CAR targeting and the proprietary PotencyPlus transgene, addressing both pediatric brain tumors and adult CNS indications including glioblastoma and brain metastases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 1 trial completed with excellent safety and tolerability outcomes for B7-H3 targeting CAR T-cell therapy
+1 more record
Product overview1 text field

BrainChild Bio is a clinical-stage biotechnology company developing a unified CAR T-cell therapy platform for central nervous system (CNS) tumors. The platform centers on recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed targeting CARs (BCB-276, BCB-214, and clinical candidates BrainChild-01 through BrainChild-04) targeting antigens including B7-H3, HER2, EGFR, and IL13Ralpha2. Lead candidate BCB-276 is an autologous B7-H3 targeting CAR T-cell therapy advancing toward a pivotal registrational trial for DIPG, while BCB-214 incorporates the proprietary PotencyPlus transgene for enhanced potency. The pipeline prioritizes pediatric brain tumors with planned expansion to adult indications including glioblastoma and brain metastases.

Product and service5 records
1BCB-276
CategoryCell Therapy / CAR-T Immunotherapy
Description

Autologous B7-H3 targeting CAR T-cell therapy for treating diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor. The therapy uses recursive intracerebroventricular dosing to bypass the blood-brain barrier and deliver potent, persistent anti-tumor effector cells. Lead candidate for BrainChild Bio, advancing toward a pivotal registrational trial following FDA Breakthrough Therapy and RMAT designations.

2BCB-214
CategoryCell Therapy / CAR-T Immunotherapy
Description

CAR-T cell therapy candidate incorporating the PotencyPlus synthetic transgene to enhance immune cell potency and counteract the immunosuppressive tumor microenvironment. Designed for near-term Phase I testing.

3BrainChild-01 (HER2-targeting CAR-T)
CategoryCell Therapy / CAR-T Immunotherapy
Description

HER2-targeting CAR T-cell therapy for CNS tumors, with results published in Nature Medicine. One of multiple single-target CAR-T candidates in the company's clinical portfolio targeting CNS tumors.

4BrainChild-03 (B7-H3-targeting CAR-T)
CategoryCell Therapy / CAR-T Immunotherapy
Description

B7-H3-targeting CAR T-cell therapy with results published in Cancer Discovery. Part of the company's multiplexed targeting strategy to overcome tumor heterogeneity and antigen escape in CNS tumors.

5BrainChild-04 (Quad-targeting CAR-T)
CategoryCell Therapy / CAR-T Immunotherapy
Description

Quad-targeting CAR-T cell therapy using multiple tumor-associated antigens (EGFR, HER2, B7-H3, IL13Ralpha2) to minimize therapeutic failures from antigen escape variants, representing the company's multiplexed targeting approach to CNS tumors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Seattle Children's launched BrainChild Bio in December 2023 to accelerate CAR T-cell therapies for children with brain tumors. Dr. Nicholas Vitanza serves as CNS CAR T-cell Lead and DIPG Research Lead at Seattle Children's, and Dr. Michael Jensen previously served as founding Chief Therapeutics Officer at Seattle Children's Therapeutics.

Strategic tierMinorTypeOthers
Description

BrainChild Bio supports Send It Foundation, which provides transformative outdoor adventures for young adults facing cancer. The partnership reflects the company's commitment to supporting young cancer survivors beyond the lab.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Previous company of BrainChild CEO Steven Brugger, acquired by GSK for $3.3B in 2022; relevant as the benchmark exit profile of BrainChild's CEO and as a vaccine/biological products comparable rather than direct CAR-T competitor.

TypeEmerging player
Description

Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies; comparable as a small-cap clinical-stage CAR-T developer facing similar regulatory, manufacturing, and capital-raise challenges.

3Carsgen Therapeutics
TypeRegional player
Description

China-based clinical-stage CAR-T developer with solid tumor pipeline including CNS indications; comparable as a CAR-T platform competitor pursuing overlapping indications, though primarily operating in Asia.

TypeDirect peer
Description

Clinical-stage cell therapy company developing CAR-T therapies for solid tumors including CNS malignancies; directly comparable as a CAR-T developer targeting solid tumors with similar regulatory and clinical validation requirements.

TypeDirect peer
Description

Clinical-stage cell therapy company developing CAR-T therapies, including for glioblastoma and other brain tumors; directly comparable as a small-cap CAR-T developer targeting CNS malignancies with similar regulatory and capital challenges.

TypeEmerging player
Description

Clinical-stage cell therapy company developing allogeneic CAR-T candidates using ARCUS gene editing; comparable as a clinical-stage CAR-T platform with similar early-stage profile and pipeline diversification strategy.

TypeEmerging player
Description

Clinical-stage cell therapy company developing CAR-T candidates with novel engineering approaches; comparable as a similarly-sized early clinical-stage CAR-T platform company pursuing indications with high unmet need.

TypeBroad incumbent
Description

Markets Kymriah, the first FDA-approved CAR-T therapy; comparable as the established CAR-T incumbent whose pediatric and solid tumor expansion ambitions create both competitive threat and potential partnership/liquidity opportunity for BrainChild.

TypeDirect peer
Description

Co-founded by BrainChild founder Dr. Michael Jensen, Umoja is developing in vivo CAR-T platform technologies; comparable as a Jensen-originated CAR-T platform company at similar early-clinical stage with shared scientific lineage.

10Bristol Myers Squibb (Juno Therapeutics)
TypeBroad incumbent
Description

BMS acquired Juno Therapeutics (co-founded by BrainChild's Dr. Jensen) and markets Breyanzi and Abecma CAR-T therapies; comparable as the broader CAR-T commercial leader and the most direct commercialization reference for Jensen-originated cell therapy platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BrainChild Bio

Cell Therapy / CAR-T Immunotherapy for CNS Tumorsbrainchildbio.com

BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system tumors, spun out of Seattle Children's in 2023 to prioritize pediatric brain tumors, primarily DIPG, with planned expansion into adult glioblastoma and brain metastases.

What BrainChild Bio does

BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for tumors of the central nervous system, with a pediatric-first pipeline anchored by lead candidate BCB-276 in diffuse intrinsic pontine glioma (DIPG), an incurable childhood brainstem cancer. The company was launched in December 2023 as a spin-off from Seattle Children's, founded by Dr. Michael Jensen — inventor of over 200 cell and gene therapy patents and co-founder of Juno Therapeutics and Umoja Biopharma — and is led by CEO Steven Brugger (formerly CEO of Affinivax, acquired by GSK for $3.3 billion in 2022).

The company's core technology is a unified CAR-T platform built on three proprietary pillars: (1) recursive intracerebroventricular dosing that delivers CAR-T cells directly into the cerebrospinal fluid, bypassing the blood-brain barrier and eliminating the need for systemic lymphodepleting chemotherapy; (2) a multiplexed targeting portfolio against EGFR, HER2, B7-H3, and IL13Ralpha2 designed to prevent therapeutic failure from antigen escape; and (3) the PotencyPlus synthetic transgene library that augments CAR-T potency in the immunosuppressive tumor microenvironment. Beyond lead candidate BCB-276, the pipeline includes BCB-214 (PotencyPlus-enhanced, near-term Phase I) and additional clinical candidates BrainChild-01 through BrainChild-04 targeting HER2, B7-H3, and a quad-targeting construct.

BrainChild Bio is pre-revenue and generates no commercial product sales today. Its economics are entirely clinical-development-stage: it funds operations through grants (e.g., a $300,000 ScaleReady G-Rex Grant in January 2025) and is positioned to monetize via commercialization of CAR-T products following FDA approval. It received FDA Breakthrough Therapy Designation in April 2025 and RMAT designation in May 2025 for its B7-H3 program, enabling an expedited pivotal registrational pathway toward BLA. The company is headquartered in Seattle with a secondary presence at the Cambridge Innovation Center, operates with 11–50 employees, and its primary customers — once commercialized — will be pediatric patients with DIPG/DMG and, on pipeline extension, adult patients with glioblastoma and brain metastases.

BrainChild Bio firmographics

Firmographics
Name
BrainChild Bio
Legal name
BrainChild Bio, Inc.
Website
https://brainchildbio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system tumors, spun out of Seattle Children's in 2023 to prioritize pediatric brain tumors, primarily DIPG, with planned expansion into adult glioblastoma and brain metastases.
Ownership category
akta.pro rank

BrainChild Bio industry classification

Industry
Product category
Cell Therapy / CAR-T Immunotherapy for CNS Tumors
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAL
Neuro-oncology

Keywords

  • CAR T-cell therapy
  • CNS tumor immunotherapy
  • Pediatric brain tumor treatment
  • Intracerebroventricular dosing
  • DIPG cell therapy

Where BrainChild Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BrainChild Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. CAR-T Therapy Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing CAR T-cell therapies for CNS tumors. Revenue will be generated through commercialization of proprietary cell therapy products following FDA approval. BCB-276 is the lead candidate for DIPG with pivotal trial pathway aligned with FDA.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

BrainChild Bio product offering

Product offering

Core offering

BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system (CNS) tumors, with lead candidate BCB-276 (an autologous B7-H3-targeting CAR T-cell therapy) advancing toward a pivotal registrational trial for diffuse intrinsic pontine glioma (DIPG). The platform uses recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed CAR targeting and the proprietary PotencyPlus transgene, addressing both pediatric brain tumors and adult CNS indications including glioblastoma and brain metastases.

Product overview

BrainChild Bio is a clinical-stage biotechnology company developing a unified CAR T-cell therapy platform for central nervous system (CNS) tumors. The platform centers on recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed targeting CARs (BCB-276, BCB-214, and clinical candidates BrainChild-01 through BrainChild-04) targeting antigens including B7-H3, HER2, EGFR, and IL13Ralpha2. Lead candidate BCB-276 is an autologous B7-H3 targeting CAR T-cell therapy advancing toward a pivotal registrational trial for DIPG, while BCB-214 incorporates the proprietary PotencyPlus transgene for enhanced potency. The pipeline prioritizes pediatric brain tumors with planned expansion to adult indications including glioblastoma and brain metastases.

Differentiator

Problem solved

Functional benefit

Products and services

  • BCB-276 Autologous B7-H3 targeting CAR T-cell therapy for treating diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor. The therapy uses recursive intracerebroventricular dosing to bypass the blood-brain barrier and deliver potent, persistent anti-tumor effector cells. Lead candidate for BrainChild Bio, advancing toward a pivotal registrational trial following FDA Breakthrough Therapy and RMAT designations.
  • BCB-214 CAR-T cell therapy candidate incorporating the PotencyPlus synthetic transgene to enhance immune cell potency and counteract the immunosuppressive tumor microenvironment. Designed for near-term Phase I testing.
  • BrainChild-01 (HER2-targeting CAR-T) HER2-targeting CAR T-cell therapy for CNS tumors, with results published in Nature Medicine. One of multiple single-target CAR-T candidates in the company's clinical portfolio targeting CNS tumors.
  • BrainChild-03 (B7-H3-targeting CAR-T) B7-H3-targeting CAR T-cell therapy with results published in Cancer Discovery. Part of the company's multiplexed targeting strategy to overcome tumor heterogeneity and antigen escape in CNS tumors.
  • BrainChild-04 (Quad-targeting CAR-T) Quad-targeting CAR-T cell therapy using multiple tumor-associated antigens (EGFR, HER2, B7-H3, IL13Ralpha2) to minimize therapeutic failures from antigen escape variants, representing the company's multiplexed targeting approach to CNS tumors.

Quantifiable outcome

  • Phase 1 trial completed with excellent safety and tolerability outcomes for B7-H3 targeting CAR T-cell therapy
  • +1 more outcomes

Companies that use BrainChild Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

BrainChild Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BrainChild Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Seattle Children's HospitalcoreStrategic or Co-development PartnerSeattle Children's launched BrainChild Bio in December 2023 to accelerate CAR T-cell therapies for children with brain tumors. Dr. Nicholas Vitanza serves as CNS CAR T-cell Lead and DIPG Research Lead at Seattle Children's, and Dr. Michael Jensen previously served as founding Chief Therapeutics Officer at Seattle Children's Therapeutics.
  • Send It FoundationminorOthersBrainChild Bio supports Send It Foundation, which provides transformative outdoor adventures for young adults facing cancer. The partnership reflects the company's commitment to supporting young cancer survivors beyond the lab.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

BrainChild Bio competitors and assessment

Company assessment

Others

  • Affinivax (acquired by GSK): Previous company of BrainChild CEO Steven Brugger, acquired by GSK for $3.3B in 2022; relevant as the benchmark exit profile of BrainChild's CEO and as a vaccine/biological products comparable rather than direct CAR-T competitor.

Emerging players

  • Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies; comparable as a small-cap clinical-stage CAR-T developer facing similar regulatory, manufacturing, and capital-raise challenges.
  • Precision BioSciences: Clinical-stage cell therapy company developing allogeneic CAR-T candidates using ARCUS gene editing; comparable as a clinical-stage CAR-T platform with similar early-stage profile and pipeline diversification strategy.
  • Cabaletta Bio: Clinical-stage cell therapy company developing CAR-T candidates with novel engineering approaches; comparable as a similarly-sized early clinical-stage CAR-T platform company pursuing indications with high unmet need.

Regional players

  • Carsgen Therapeutics: China-based clinical-stage CAR-T developer with solid tumor pipeline including CNS indications; comparable as a CAR-T platform competitor pursuing overlapping indications, though primarily operating in Asia.

Direct peers

  • Tessa Therapeutics: Clinical-stage cell therapy company developing CAR-T therapies for solid tumors including CNS malignancies; directly comparable as a CAR-T developer targeting solid tumors with similar regulatory and clinical validation requirements.
  • Mustang Bio: Clinical-stage cell therapy company developing CAR-T therapies, including for glioblastoma and other brain tumors; directly comparable as a small-cap CAR-T developer targeting CNS malignancies with similar regulatory and capital challenges.
  • Umoja Biopharma: Co-founded by BrainChild founder Dr. Michael Jensen, Umoja is developing in vivo CAR-T platform technologies; comparable as a Jensen-originated CAR-T platform company at similar early-clinical stage with shared scientific lineage.

Broad incumbents

  • Novartis: Markets Kymriah, the first FDA-approved CAR-T therapy; comparable as the established CAR-T incumbent whose pediatric and solid tumor expansion ambitions create both competitive threat and potential partnership/liquidity opportunity for BrainChild.
  • Bristol Myers Squibb (Juno Therapeutics): BMS acquired Juno Therapeutics (co-founded by BrainChild's Dr. Jensen) and markets Breyanzi and Abecma CAR-T therapies; comparable as the broader CAR-T commercial leader and the most direct commercialization reference for Jensen-originated cell therapy platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BrainChild Bio social profiles

Digital presence

BrainChild Bio compliance and trust

Trust signal

Compliance3 records

BrainChild Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BrainChild Bio leadership team

Management profile

Number of profiles

Profiles10 records

BrainChild Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BrainChild Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainChild Bio

What does BrainChild Bio do?

BrainChild Bio is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for central nervous system (CNS) tumors, with lead candidate BCB-276 (an autologous B7-H3-targeting CAR T-cell therapy) advancing toward a pivotal registrational trial for diffuse intrinsic pontine glioma (DIPG). The platform uses recursive intracerebroventricular dosing to bypass the blood-brain barrier, combined with multiplexed CAR targeting and the proprietary PotencyPlus transgene, addressing both pediatric brain tumors and adult CNS indications including glioblastoma and brain metastases.

Is BrainChild Bio a public or private company?

BrainChild Bio is a private company. It is classified as unknown and is currently operating.

When was BrainChild Bio founded?

BrainChild Bio was founded in 2023. It employs 51 to 100 people.

Where is BrainChild Bio based?

BrainChild Bio is headquartered in Seattle, United States, in the North America region.

How does BrainChild Bio make money?

One revenue line is on record: CAR-T Therapy Development and Commercialization.

Who are BrainChild Bio's main competitors?

Affinivax (acquired by GSK) is listed as an others. Emerging players are Caribou Biosciences, Precision BioSciences and Cabaletta Bio. Carsgen Therapeutics is listed as a regional player. Direct peers are Tessa Therapeutics, Mustang Bio and Umoja Biopharma. Broad incumbents are Novartis and Bristol Myers Squibb (Juno Therapeutics).

Does BrainChild Bio have an API?

No public API is recorded for BrainChild Bio.

What industry is BrainChild Bio in?

BrainChild Bio's product category is Cell Therapy / CAR-T Immunotherapy for CNS Tumors. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumEncoded raises $275m for Dravet therapy and other financingsEncoded Therapeutics raised $275 million to advance its Dravet syndrome gene therapy ETX101 into a pivotal trial, following phase 1/2 POLARIS data showing reduced seizure frequency. The funding will also support manufacturing scale-up and development of a second drug candidate, ETX301, for post-amputation pain.WebProNewsBrainChild Bio Raises $116M to Tackle Deadly Childhood Brainstem Cancer With CAR T CellsBrainChild Bio raised $116 million in a Series A led by an undisclosed private family fund and foundation, with Seattle Children's participating. The funds will advance its lead CAR T therapy BCB-276 through a registrational Phase 2 trial for diffuse intrinsic pontine glioma, with topline data expected in 2028.GeekWireSeattle biotech BrainChild Bio raises $116M to advance CAR T therapy for childhood brain cancerBrainChild Bio raised $116 million in a Series A led by an undisclosed private family fund and foundation, with participation from Seattle Children's and WRF Capital. The funds will support a Phase 2 trial of a CAR T cell therapy for diffuse intrinsic pontine glioma, a rare brainstem tumor affecting children ages 5-10. The company also plans to advance a CAR T therapy for glioblastoma.Pulse 2.0BrainChild Bio Raises $116 Million Series A And Launches Pivotal Phase 2 CAR T Cell Trial For Pediatric Brain CancerBrainChild Bio raised $116 million in Series A funding to advance its CAR T cell therapies for central nervous system tumors. The company initiated a pivotal Phase 2 trial of BCB-276 for diffuse intrinsic pontine glioma, with the trial designed as a registrational study. Proceeds will also support development of BCB-214 for glioblastoma.GenengnewsWith $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s BrainstemsBrainChild Bio raised $116 million in Series A financing to fund a pivotal registrational trial for its CAR T cell therapy BCB-276, targeting diffuse intrinsic pontine glioma. The Phase II ILLUMINATE trial, which has dosed its first patient, aims to assess overall survival and could lead to a BLA filing. The company plans to enter BCB-214 for glioblastoma next year.BioPharma DiveBrainChild hauls in $116M to make cell therapies for childhood brain cancersBrainChild Bio raised $116 million in a Series A round to develop CAR-T cell therapies for children with rare brain cancers. Its BCB-276 is in Phase 2 for diffuse intrinsic pontine glioma, and BCB-214 is in preclinical development for glioblastoma. The company plans to start human testing for BCB-214 next year.Venture Capital Access OnlineBrainChild Bio Closes $116 Million Series A FinancingBrainChild Bio closed a $116 million Series A financing led by an undisclosed private family fund and foundation. Proceeds will fund the ILLUMINATE Phase 2 trial for BCB-276, a CAR T cell therapy for diffuse intrinsic pontine glioma, and support early pipeline programs.BioSpaceBrainChild Bio targets deadly brain cancer in children with $116M series ABrainChild Bio raised $119 million in a series A to advance CAR T therapies for pediatric brain cancers. The funds will support the Phase 2 ILLUMINATE study of BCB-276 for diffuse intrinsic pontine glioma, with topline data expected in 2028. The company also plans initial clinical testing for BCB-214.FinSMEsBrainChild Bio Closes $116M Series A FinancingBrainChild Bio raised $116M in Series A funding led by an undisclosed private family fund and foundation, with participation from Seattle Children's and WRF Capital. The company will use the funds to support the ILLUMINATE Phase 2 study of BCB-276 for DIPG and continued development of BCB-214 for glioblastoma.BioWorldBrainchild secures $116M for its CAR T for childhood brain cancerBrainchild Bio Inc. raised $116 million in Series A financing to develop CAR T cell therapy for childhood brain cancer. The round was led by an undisclosed private family fund and foundation, with participation from Seattle Children's and WRF Capital.